We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: As Poor Nations Seek Covid Pills, Officials Fear Repeat of AIDS Crisis
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Politics > As Poor Nations Seek Covid Pills, Officials Fear Repeat of AIDS Crisis
As Poor Nations Seek Covid Pills, Officials Fear Repeat of AIDS Crisis
Politics

As Poor Nations Seek Covid Pills, Officials Fear Repeat of AIDS Crisis

Last updated: May 8, 2022 9:00 am
Editorial Board Published May 8, 2022
Share
SHARE
05dc covid diplo1 sub facebookJumbo

The cost to UNICEF of Paxlovid — including Pfizer’s insistence that UNICEF keep how much it pays confidential — remains a sticking point, said Dr. Philippe Duneton, who runs the therapeutics arm of the W.H.O. consortium. In announcing its “strong recommendation” for Paxlovid, the W.H.O. took the highly unusual step of publicly scolding Pfizer for a “lack of transparency,” which makes it difficult to know which countries have the drug and what they are paying.

“We need to have better visibility in terms of price,” Dr. Duneton said.

Manufacturers often prefer that the details of their sales agreements be secret so as not to weaken their hand with other potential buyers. Pfizer’s chief executive, Albert Bourla, reported last week that Paxlovid had been a “key growth driver” for the company, which is using a “tiered pricing approach” in which low- and lower-middle-income countries will get Paxlovid at a not-for-profit price.

In response to an inquiry from The New York Times, Pfizer issued a statement saying that it was “deeply disappointed by the sentiment expressed by our partners,” adding, “We have in good faith heard and responded to many of their concerns.”

Both Pfizer and Merck have also taken steps to make inexpensive generic versions of their pills available, signing licensing agreements with the Medicines Patent Pool, which was created during the global AIDS crisis to bring drugs to low- and middle-income nations at low cost. It took years, and bitter fights between activists and companies, to reach such agreements for H.I.V. drugs.

But the agreements for Covid antivirals do not apply to many middle-income nations, including much of Latin America and parts of northern Africa and Asia. The result, experts say, is that both poor and rich nations will have access, but countries in the middle will have to negotiate with the companies — or force the drugmakers to turn over their intellectual property.

So far, 36 companies from 12 countries have signed up to make generic Paxlovid. Companies in India are already making generic versions of both Paxlovid and molnupiravir. The expectation is that both drugs will ultimately be available in about 100 low- and middle-income countries, covering about half the world’s population. The companies will not receive royalties from the sales while the W.H.O.’s declaration of the pandemic as a global health emergency remains in effect.

“Given the severity of the pandemic and given the fact that vaccines had a very uneven penetration rate, we felt that this was a very important contribution the company could make,” said Paul Schaper, executive director for global public policy at Merck.

You Might Also Like

State Sen. Brad Hoylman-Sigal mixed items to create his Manhattan co-op

Rep. Nadler staffer ‘traumatized’ after DHS cuffs her in NYC congressional workplace

FBI investigating impersonator who hacked cellphone of Chief of Employees Susie Wiles

LEONARD GREENE: From upstart activist to political large, Charles Rangel’s loss of life marks finish of an period

Trump teases potential pardon if Sean ‘Diddy’ Combs is convicted

TAGGED:Acquired Immune Deficiency SyndromeCoronavirus (2019-nCoV)Drugs (Pharmaceuticals)Income InequalityMolnupiravir (Drug)Paxlovid (Drug)Tests (Medical)The Washington MailUnited States International RelationsWorld Health Organization
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Nets Pocket book: Day’Ron Sharpe may make season debut “at some point this week”
Sports

Nets Pocket book: Day’Ron Sharpe may make season debut “at some point this week”

Editorial Board December 1, 2024
Alex Ovechkin scores his 872nd profession objective because the Capitals beat the struggling Rangers 7-4
Karl-Anthony Cities (thumb) to play by the ache; Tom Thibodeau not anxious by OG Anunoby’s current hunch
It Took Me 40 Years to Watch the Movie ‘Diva.’ It Was Worth the Wait.
Playboi Carti, rap’s Nosferatu, sails into city with ‘Music’ at Rolling Loud

You Might Also Like

PBS suing Trump administration over defunding, three days after NPR filed comparable case
Politics

PBS suing Trump administration over defunding, three days after NPR filed comparable case

May 30, 2025
Elon Musk closely used medication whereas campaigning for Trump: report
Politics

Elon Musk closely used medication whereas campaigning for Trump: report

May 30, 2025
Bronx highschool scholar Dylan detained by ICE asks decide to order his launch
Politics

Bronx highschool scholar Dylan detained by ICE asks decide to order his launch

May 30, 2025
NYC Marketing campaign Finance Board withholds .3M in matching funds from Cuomo, awards Adrienne Adams M
Politics

NYC Marketing campaign Finance Board withholds $1.3M in matching funds from Cuomo, awards Adrienne Adams $2M

May 30, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?